Ready for Transfer

Intranasal Dry Powder Inhaler

RFT image

Laboratory: Centers for Disease Control and Prevention (CDC)

Technology: Intranasal Dry Powder Inhaler (DPI)

Opportunity: The DPI technology is available for license through NIH’s Office of Intramural Research, Office of Technology Transfer.

Details: CDC developed the DPI technology with the help of Creare, Inc., to provide a low-cost powder delivery alternative of vaccines and therapeutics when compared to traditional injected vaccines.

Benefits: Aside from being extremely cost-effective, there are numerous benefits of the DPI technology, such as safe, needle-less delivery that can be self-administered. This new therapeutic delivery technology also reduces biohazard waste and is highly thermostable, meaning it may not require cold chain storage.

Applications: The DPI technology has applications in the following areas:

  • Intranasal delivery of vaccines and therapeutics
  • Childhood vaccination programs
  • Large-scale immunization campaigns
  • Use for response to disease epidemics.

Contact: For more information about this technology, please contact Karen Surabian in the NIH Office of Intramural Research’s Office of Technology Transfer at